BioSpace News Archive

Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases, today announced it has received a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT).

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that two poster presentations supporting the efficacy and safety of dihydroergotamine (DHE) for the acute treatment of migraine were selected for presentation at the American Headache Society’s (AHS) Annual Scientific Meeting.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that Chairman, President and Chief Executive Officer, Scott Ward, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18 at 1:40 p.m. Eastern Time.

Scopus BioPharma Inc. (“Scopus” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting serious diseases with significant unmet medical needs, today announced the signing of an exclusive, worldwide license to a novel, first-in-class, targeted immuno-oncology gene therapy drug developed at City of Hope.

Mirum Pharmaceuticals, Inc. announced that the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of common stock to two new employees under Mirum’s 2020 Inducement Plan.

The Board of Directors of Bristol Myers Squibb (NYSE:BMY) today declared a quarterly dividend of forty-five cents ($0.45) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 3, 2020, to stockholders of record at the close of business on July 6, 2020. The directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, has signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc., a biopharmaceutical company focused on novel therapeutics for serious diseases with significant unmet medical needs.

VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, today announced that results from the company’s VAST study, a 12-month trial evaluating VIA Disc®, a non-surgical, injectable intradiscal treatment option for patients suffering from degenerative disc disease (DDD), will be presented at The Orthobiologic Institute’s (TOBI) virtual 11th Annual Orthobiologics Symposium

UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive

While studying the effects of androgens on hair loss, Applied Biology scientists discovered an association between baldness (androgenetic alopecia) and the risk of COVID-19 disease severity.